<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104038">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696461</url>
  </required_header>
  <id_info>
    <org_study_id>09-PLEX</org_study_id>
    <nct_id>NCT01696461</nct_id>
  </id_info>
  <brief_title>A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor</brief_title>
  <official_title>A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for International Blood and Marrow Transplant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for International Blood and Marrow Transplant Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, open-label, two strata, multicenter, prospective study of
      plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological
      malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor
      for this purpose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of donors whose cells can be successfully mobilized and collected with a sufficient CD34+ cell dose using plerixafor as the mobilizing agent, using an intention-to-treat analysis</measure>
    <time_frame>donation</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the proportion of donors whose cells can be successfully mobilized and collected with a sufficient CD34+ cell dose using plerixafor as the mobilizing agent, using an intention-to-treat analysis.   Donor mobilization following plerixafor will be considered successful if â‰¥ 2.0x106 CD34+ cells/kg recipient weight are collected in no more than two leukapheresis collections. All donors receiving plerixafor will be included in the analysis of the primary objective based on the intention-to-treat principle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of acute toxicities before and during apheresis experienced by donors receiving plerixafor</measure>
    <time_frame>baseline, donation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To ascertain the incidence and severity of acute toxicities before and during apheresis experienced by donors receiving plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the adverse effects experienced by donors receiving plerixafor up to one year post donation</measure>
    <time_frame>baseline, donation, 1 week, 1 month, 6 months, 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To characterize the adverse effects experienced by donors receiving plerixafor up to one year post donation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of and kinetics of neutrophil and platelet recovery after transplantation of hematopoietic cells mobilized with plerixafor</measure>
    <time_frame>Day 21, 28, 56, 100, 180, 270, 365</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the incidence of and kinetics of neutrophil and platelet recovery after transplantation of hematopoietic cells mobilized with plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of T-cell (CD3+) and myeloid (CD33+) chimerism after transplantation of hematopoietic cells mobilized with plerixafor</measure>
    <time_frame>Day 28, 100, 180, 365</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe T-cell (CD3+) and myeloid (CD33+) chimerism after transplantation of hematopoietic cells mobilized with plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary and secondary graft failure after transplantation of hematopoietic cells mobilized with plerixafor</measure>
    <time_frame>Day 21, 28, 56, 100, 180, 270, 365</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the incidence of primary and secondary graft failure after transplantation of hematopoietic cells mobilized with plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic graft-versus host disease (GVHD) after transplantation of hematopoietic cells mobilized with plerixafor</measure>
    <time_frame>Day 21, 28, 56, 100, 180, 270, 365</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the incidence of acute and chronic graft-versus host disease (GVHD) after transplantation of hematopoietic cells mobilized with plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and quality of immune reconstitution as evidenced by peripheral blood immunophenotype after transplantation of hematopoietic cells mobilized with plerixafor</measure>
    <time_frame>Day 28, 100, 180, 365</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the rate and quality of immune reconstitution as evidenced by peripheral blood immunophenotype after transplantation of hematopoietic cells mobilized with plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of CMV reactivation after transplantation of hematopoietic cells mobilized with plerixafor in CMV seropositive recipients</measure>
    <time_frame>Day 100, 180, 365</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the incidence of CMV reactivation after transplantation of hematopoietic cells mobilized with plerixafor in CMV seropositive recipients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of treatment-related mortality and disease relapse/progression after transplantation of hematopoietic cells mobilized with plerixafor</measure>
    <time_frame>Day 21, 28, 56, 100, 180, 270, 365</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the incidence of treatment-related mortality and disease relapse/progression after transplantation of hematopoietic cells mobilized with plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>probability of progression-free and overall survival after transplantation of hematopoietic cells mobilized with plerixafor</measure>
    <time_frame>Day 21, 28, 56, 100, 180, 270, 365</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the probability of progression-free and overall survival after transplantation of hematopoietic cells mobilized with plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe the cellular composition of allografts mobilized with plerixafor (stem/progenitor cells, T/B/NK-cells)</measure>
    <time_frame>donation</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe the cellular composition of allografts mobilized with plerixafor (stem/progenitor cells, T/B/NK-cells)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>For Donors:</condition>
  <condition>Related Donors Donating PBSC to a Family Member</condition>
  <condition>For Recipients:</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Related donors receiving plerixafor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <arm_group_label>Related donors receiving plerixafor</arm_group_label>
    <other_name>Mozobil</other_name>
    <other_name>AMD3000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Donor:

          -  Donor eligibility will be determined according to applicable federal, state and local
             regulations and institutional standards

          -  18-65 years of age

          -  6/6 HLA-matched sibling

          -  Fulfill individual Transplant Center criteria to serve as a mobilized blood cell
             donor

          -  Serum creatinine &lt;2.0mg/dl

        Recipient:

          -  18 to 65 years of age

          -  6/6 HLA antigen matched sibling willing to donate PBSC for transplant

          -  Fulfill individual Transplant Center Criteria for transplant

          -  One of the following diagnoses:

               -  Acute myelogenous leukemia (AML) in 1st remission or beyond with &lt;5% marrow
                  blasts and no circulating blasts.  Marrow must be done within 30 days of the
                  start of transplant conditioning regimen in alignment with other pre-transplant
                  assessments.

               -  Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with &lt;5% marrow
                  blasts and no circulating blasts

               -  Myelodysplastic syndrome, either intermediate-1,2, or high risk by International
                  Prognostic Scoring System or transfusion dependent

               -  Chronic myelogenous leukemia (CML) failing or intolerant to tyrosine kinase
                  inhibitor based therapy

               -  Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater
                  complete remission, partial remission, or in relapse (but with at least stable
                  disease after most recent therapy)

               -  Chronic lymphocytic leukemia (CLL), relapsing after at least one prior regimen,
                  or in remission with 17p deletion

          -  Serum creatinine must be &lt;2.0mg/dl

          -  Total bilirubin and AST &lt;3x normal

          -  Infectious disease marker (IDM) monitoring will be performed per institutional
             standards

          -  Karnofsky performance status of 70% or greater.

          -  Patients who have undergone a prior autologous transplantation are eligible for a
             reduced intensity transplant only

        Exclusion Criteria:

        Donor:

          -  Donor unwilling or unable to give informed consent, or unable to comply with the
             protocol including required follow-up and testing

          -  Donor already enrolled on another investigational agent study

          -  Pregnant or breast feeding females, or females not willing or able to use adequate
             contraception if sexually active

        Recipient:

          -  Patient unwilling or unable to give informed consent, or unable to comply with the
             protocol including required follow-up and testing

          -  Patients with active, uncontrolled infection at the time of the transplant
             preparative regimen

          -  Pregnant or breast feeding females, or females not willing or able to use adequate
             contraception if sexually active

          -  Patients with a history of previous CNS tumor involvement showing active symptoms or
             signs along with documented disease on lumbar puncture and MRI of the brain within 30
             days of start of conditioning

          -  A condition, which, in the opinion of the clinical investigator, would interfere with
             the evaluation of primary and secondary endpoints.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Devine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie Spiess</last_name>
    <phone>612-884-8787</phone>
    <email>lspiess2@nmdp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Fernandez, MD</last_name>
      <email>hugo.fernandez@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ned Waller, MD</last_name>
      <email>ewaller@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Artz, MD</last_name>
      <email>aartz@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Bin Chen, MD</last_name>
      <email>ychen6@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian McClune, DO</last_name>
      <email>bmcclune@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Litzow, MD</last_name>
      <email>litzow.mark@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John DiPersio, MD</last_name>
      <email>jdipersi@im.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitch Horwitz, MD</last_name>
      <email>mitchell.horwitz@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ed Copelan, MD</last_name>
      <email>copelae@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Devine, MD</last_name>
      <email>steven.devine@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Craig, MD</last_name>
      <email>craigm@wvuhealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi Hamadani, MD</last_name>
      <email>mhamadani@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>September 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
